Retigabine as add-on treatment of refractory epilepsy - a cost-utility study in a Swedish setting
Authors:
- 31 January 2013
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 127 (6) , 419-426
Abstract
In Undetermined OBJECTIVES: To calculate comparative incremental cost-effectiveness ratios (cost per quality-adjusted life year, QALY) and net marginal benefits for retigabine as add-on treatment for patients with uncontrolled focal seizures as compared to add-on lacosamide treatment and no add-on treatment, respectively. MATERIALS & METHODS: Calculations were performed using a validated decision-tree model. The study population consisted of adult patients with focal-onset epilepsy in published randomized placebo-controlled add-on trials of retigabine or lacosamide. Healthcare utilization and QALY for each treatment alternative were calculated. Probabilistic sensitivity analysis was performed using the specification of this model as a basis for Monte Carlo simulations. 2009 prices were used for all costs. RESULTS: Results were reported for a 2-year follow-up period. Retigabine add-on treatment was both more effective and less costly than lacosamide add-on treatment, and the cost per additional QALY for the retigabine no add-on (standard) therapy comparison was estimated at 2009€ 15,753. Using a willingness-to-pay threshold for a QALY of € 50,000, the net marginal values were estimated at 2009€ 605,874 for retigabine vs lacosamide and 2009€ 2,114,203 for retigabine vs no add-on, per 1,000 patients. The probabilistic analyses showed that the likelihood that retigabine treatment is cost-effective is at least 70%. CONCLUSIONS: The estimated cost per additional QALY, for the retigabine vs no add-on treatment comparison, is well within the range of newly published estimates of willingness to pay for an additional QALY. Thus, add-on retigabine treatment for people with focal-onset epilepsy with no/limited response to standard antiepileptic treatment appears to be cost-effectiveKeywords
This publication has 26 references indexed in Scilit:
- Cost Effectiveness of Lacosamide in the Adjunctive Treatment of Patients with Refractory Focal Epilepsy in BelgiumCNS Drugs, 2012
- Willingness to Pay for a Quality-Adjusted Life-Year: The Individual PerspectiveValue in Health, 2010
- Economic Burden of Epilepsy among the Privately Insured in the USPharmacoEconomics, 2010
- Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United StatesEpilepsia, 2010
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trialEpilepsia, 2009
- Cost of EpilepsyPharmacoEconomics, 2008
- Cost‐effectiveness of Add‐on Therapy with Pregabalin in Patients with Refractory Partial EpilepsyEpilepsia, 2007
- Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset SeizuresEpilepsia, 2007
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004